Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells-Reference-Cited by-同舟云学术

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

Published:2018-01-18 Issue:2 Volume:9 Page:
ISSN:2041-4889
Container-title:Cell Death & Disease
language:en
Short-container-title:Cell Death Dis

Author:

Augello Giuseppa,Modica Martina,Azzolina Antonina,Puleio Roberto^ORCID,Cassata Giovanni,Emma Maria Rita,Di Sano Caterina,Cusimano Antonella,Montalto Giuseppe,Cervello Melchiorre

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/s41419-017-0195-0.pdf

Reference42 articles.

1. Torrecilla, S. & Llovet, J. M. New molecular therapies for hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. 39, 80–85 (2015).

2. Curran, M. P. & McKeage, K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs 69, 859–888 (2009).

3. O’Connor, O. A. et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J. Clin. Oncol. 23, 676–684 (2005).

4. Lee, A. H., Iwakoshi, N. N., Anderson, K. C. & Glimcher, L. H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. USA 100, 9946–9951 (2003).

5. Jiang, H. Y. & Wek, R. C. Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. J. Biol. Chem. 280, 14189–14202 (2005).

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches;Molecular Cancer;2024-07-25

2. Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer;Cell Death Discovery;2024-01-29

3. RNF126, 168 and CUL1: The Potential Utilization of Multi-Functional E3 Ubiquitin Ligases in Genome Maintenance for Cancer Therapy;Biomedicines;2023-09-13

4. Inhibitory effort of MLN2238 on basal-like breast cancer: An investigation based on the gene set enrichment analysis;Cellular and Molecular Biology;2023-07-31

5. Role of Atractylenolide I in Cerebral Ischemia Reperfusion Injury;Revista Brasileira de Farmacognosia;2023-04-01